TAS-115, a novel multi-kinase inhibitor, demonstrated antifibrotic effectsin vitroandin vivo.#This is an open-label, intra-patient comparison, exploratory phase 2 study of TAS-115 to evaluate the efficacy and safety in idiopathic pulmonary fibrosis (IPF) patients when orally administered at 200mg...
Several studies suggest that TAS-115 may exert beneficial effects on pulmonary fibrosis by targeting the M-CSF as well as PDGFR.Methods: This study evaluated the efficacy and safety of TAS-115 in idiopathic pulmonary fibrosis (IPF) patients (pts) including decrease of % FVC after or unfit for...